Tuesday, March 12, 2013

Register today for the Gross-to-Net Accounting Forum

Ensuring your Gross-to-Net calculations are accurate is a messy business, but a necessary one. In the GTN space, the pharmaceutical industry has just recently begun to open up about forecasting and accruing for liability or working interdepartmentally between the commercial and government sectors.

At IIR’s Gross –to-Net Accounting Forum for Manufacturers we know how important it is for you to be able to benchmark your systems and methodologies against best practices. For that reason, we have developed unique formats whereby our session leaders and our audience interact before and during the event to ensure your most pressing GTN questions are answered when you are in Boston.

Some of these interactive session highlights include:
  • Top 10 GTN Hot Topics to Benchmark Your Gross-to-Net Processes, Systems & Methodologies:  This valuable benchmarking exercise focuses on GTN organization/process design, system implementation, contract analytics, performance monitoring, contract forecasting, accruals, SOP/SOX documentation and management reporting. A live, dynamic audience poll on hot topics as well as industry case studies will get you “in the know” with how your peers are getting to their calculations.
  • How Big Pharma Is Managing Gross-to-Net Processes : If you did not know there was a GTN Best Practices Industry Group, you do now! This session will highlight the latest best practice results, providing the attendees with guidance to take home and add to their GTN strategies. Interactive dialogue ensures no topic is left without a discussion.
To find out more about the 2013 program, download the agenda.

As a reader of Gross-to-Net blog, you get a 15% discount off the standard rate when using code XP1811BLOG to register. If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

We look forward to seeing you this June!

Gross-to-Net Forum Team

Visit our homepage
Follow us on Twitter

No comments: